Klinische und biochemische Resultate bei der Behandlung mit Marvelon - einem neuen steroidalen Ovulationshemmer

Marvelon was tolerated without side effects by 338 women during 2104 cycles. Although some errors of administration were made by patients there were no pregnancies. In contradistinction to other low dose oral combination contraceptives (OCs) this new OC has a good control over the menstrual cycle. The incidence of clinical side effects was low. An oversuppression syndrone after the discontinuation of the treatment was not observed. Hormonal assays were done in order to investigate the difficult problems of oligomenorrhea in adolescents with OCs. A marked inhibition of ovulation as evidenced by low values of pituitary ovarian hormones was found. When the treatment was discontinued the majority of the patients showed ovulation in the 1st posttreatment cycle. (authors) (summary in ENG)